DE2001265A1 - Bakteriophagen-Protein-Konjugate,deren Herstellung und Verwendung zum Nachweis und zur quantitativen Bestimmung von Proteinen - Google Patents
Bakteriophagen-Protein-Konjugate,deren Herstellung und Verwendung zum Nachweis und zur quantitativen Bestimmung von ProteinenInfo
- Publication number
- DE2001265A1 DE2001265A1 DE19702001265 DE2001265A DE2001265A1 DE 2001265 A1 DE2001265 A1 DE 2001265A1 DE 19702001265 DE19702001265 DE 19702001265 DE 2001265 A DE2001265 A DE 2001265A DE 2001265 A1 DE2001265 A1 DE 2001265A1
- Authority
- DE
- Germany
- Prior art keywords
- protein
- bacteriophage
- inactivation
- phage
- conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 title claims description 37
- 108090000623 proteins and genes Proteins 0.000 title claims description 37
- 238000001514 detection method Methods 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 51
- 230000002779 inactivation Effects 0.000 claims description 36
- 229940125396 insulin Drugs 0.000 claims description 28
- 241001515965 unidentified phage Species 0.000 claims description 27
- 102000004877 Insulin Human genes 0.000 claims description 23
- 108090001061 Insulin Proteins 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 230000001588 bifunctional effect Effects 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- 108010071390 Serum Albumin Proteins 0.000 claims description 3
- 102000007562 Serum Albumin Human genes 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 claims description 2
- 125000005442 diisocyanate group Chemical group 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims 1
- 108700010839 phage proteins Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 27
- 239000000243 solution Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229960000587 glutaral Drugs 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000701542 Enterobacteria phage T2 Species 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- YUJSWFZLUCHGFO-UHFFFAOYSA-N 4-(4-azidophenyl)aniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 YUJSWFZLUCHGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 230000001130 anti-lysozyme effect Effects 0.000 description 1
- 230000001188 anti-phage Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/802—Protein-bacteriophage conjugates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB269769 | 1969-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2001265A1 true DE2001265A1 (de) | 1971-05-27 |
Family
ID=9744207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19702001265 Pending DE2001265A1 (de) | 1969-01-16 | 1970-01-13 | Bakteriophagen-Protein-Konjugate,deren Herstellung und Verwendung zum Nachweis und zur quantitativen Bestimmung von Proteinen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3717705A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5037253B1 (cg-RX-API-DMAC7.html) |
| BE (1) | BE744478A (cg-RX-API-DMAC7.html) |
| CA (1) | CA956237A (cg-RX-API-DMAC7.html) |
| CH (1) | CH546405A (cg-RX-API-DMAC7.html) |
| DE (1) | DE2001265A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2028475A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1303802A (cg-RX-API-DMAC7.html) |
| IL (1) | IL33718A (cg-RX-API-DMAC7.html) |
| NL (1) | NL7000571A (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166767A (en) * | 1976-03-25 | 1979-09-04 | Dainippon Pharmaceutical Co., Ltd. | Insolubilized antibody |
| FR2441847A1 (fr) * | 1978-11-14 | 1980-06-13 | Serres Pierre Francois | Procede pour la detection quantitative et qualitative des antigenes, anticorps et haptenes |
| US4797363A (en) * | 1984-03-19 | 1989-01-10 | Board Of Trustees, University Of Illinois | Bacteriophages as recognition and identification agents |
| EP0175761A4 (en) * | 1984-03-19 | 1986-09-24 | Marius Constantin Teodorescu | BACTERIOPHAGES SERVING RECOGNITION AND IDENTIFICATION AGENTS. |
| FR2581313A1 (fr) * | 1985-05-02 | 1986-11-07 | Pasteur Institut | Composes suscitant la formation d'anticorps, compositions immunogeniques et compositions immunoprotectrices les contenant et procede d'obtention d'anticorps les mettant en oeuvre |
| EP0298094A1 (en) * | 1986-12-01 | 1989-01-11 | McDONNELL DOUGLAS CORPORATION | Method of identifying salmonella |
| US5168037A (en) * | 1990-08-02 | 1992-12-01 | Phyllis Entis | Method for the preparation of a labelled virus without the inactivation of viral binding sites and method of assay utilizing said labelled virus |
| AU679228B2 (en) * | 1993-04-27 | 1997-06-26 | Symbiotech, Inc. | Method of detecting compounds utilizing chemically modified lambdoid bacteriophage |
| US5679510A (en) * | 1993-04-27 | 1997-10-21 | Hybridon, Inc. | Quantitative detection of specific nucleic acid sequences using lambdoid bacteriophages linked by oligonucleotides to solid support |
| US5650267A (en) * | 1993-04-27 | 1997-07-22 | Symbiotech, Inc. | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
| AU7104294A (en) * | 1994-06-10 | 1996-01-05 | Symbiotech, Inc. | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
| EP1963494B1 (en) * | 2005-11-29 | 2014-10-08 | The Trustees of The University of Pennsylvania | Phage particle diagnostic reagents |
| US20120045748A1 (en) * | 2010-06-30 | 2012-02-23 | Willson Richard C | Particulate labels |
| CN117618557A (zh) * | 2023-10-23 | 2024-03-01 | 西北工业大学 | 一种噬菌体介导靶向光敏剂及其制备方法和应用 |
-
1969
- 1969-01-16 GB GB269769A patent/GB1303802A/en not_active Expired
-
1970
- 1970-01-09 US US00001848A patent/US3717705A/en not_active Expired - Lifetime
- 1970-01-12 CA CA071,928A patent/CA956237A/en not_active Expired
- 1970-01-13 DE DE19702001265 patent/DE2001265A1/de active Pending
- 1970-01-14 CH CH47570A patent/CH546405A/xx not_active IP Right Cessation
- 1970-01-15 NL NL7000571A patent/NL7000571A/xx unknown
- 1970-01-15 IL IL33718A patent/IL33718A/en unknown
- 1970-01-15 BE BE744478D patent/BE744478A/xx unknown
- 1970-01-16 JP JP45004374A patent/JPS5037253B1/ja active Pending
- 1970-01-16 FR FR7001597A patent/FR2028475A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NL7000571A (cg-RX-API-DMAC7.html) | 1970-07-20 |
| IL33718A0 (en) | 1970-03-22 |
| FR2028475A1 (cg-RX-API-DMAC7.html) | 1970-10-09 |
| US3717705A (en) | 1973-02-20 |
| JPS5037253B1 (cg-RX-API-DMAC7.html) | 1975-12-01 |
| BE744478A (fr) | 1970-06-15 |
| IL33718A (en) | 1973-05-31 |
| CH546405A (de) | 1974-02-28 |
| GB1303802A (cg-RX-API-DMAC7.html) | 1973-01-24 |
| CA956237A (en) | 1974-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2743444C3 (de) | Immunchemisches Meßverfahren und Reagens zu seiner Durchführung | |
| Cinader et al. | Acquired immune tolerance to human albumin and the response to subsequent injections of diazo human albumin | |
| Heding | Determination of total serum insulin (IRI) in insulin-treated diabetic patients | |
| DE60026691T2 (de) | Staphylococcus-antigene und impstoffe | |
| DE3590392C2 (cg-RX-API-DMAC7.html) | ||
| DE2202441B2 (de) | Barbitursäureantigene und spezifische Antikörper hierfür | |
| DE2805663C3 (cg-RX-API-DMAC7.html) | ||
| DE2816841A1 (de) | Radioimmunologische bestimmung von prokollagen (typ iii) und prokollagen- peptid (typ iii) | |
| DE3224788A1 (de) | Traegergebundenes immunogenes material | |
| The et al. | Conjugation of fluorescein isothiocyanate to antibodies: II. A reproducible method | |
| Coombs et al. | The conglutination phenomenon IX. The production of immuno-conglutinin in rabbits | |
| DE3117725A1 (de) | Verfahren zur bestimmung von mycobakterien und protein sowie fertigpack zu dessen durchfuehrung | |
| EP0013930B1 (de) | Immunogen, Antikörper für ein Thymus-Hormon, markiertes Thymus-Hormon und Verfahren zur Bestimmung dieses Thymushormons | |
| DE69032855T2 (de) | Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung | |
| DE2322562C2 (de) | Verfahren zur Bestimmung von Antigenen in einer Probe | |
| DE69132122T2 (de) | Reinigung von cytokeratinfragmenten | |
| US3717705A (en) | Protein-bacteriophage conjugates | |
| DE2531176A1 (de) | Verfahren zum nachweis von gonorrhoeantikoerpern | |
| EP0209155B1 (de) | Konjugat für die Enzymimmunobestimmung | |
| DE3224217A1 (de) | Enzymimmunoassay-methode zur qualitativen und quantitativen bestimmung von substanzen | |
| Brunfeldt et al. | Antibodies in the pig against pig insulin | |
| DE2551576A1 (de) | Traeger fuer immunochemische messungen | |
| DE2310280A1 (de) | Tubocurarin-antigene | |
| CH645727A5 (de) | Praeparat zur bestimmung von menschlichem beta-2-mikroglobulin, verfahren zu seiner herstellung und seine verwendung. | |
| DE2814121C3 (de) | Verfahren zur Herstellung eines bei der Krebs-Diagnose verwendbaren spezifischen Immunserums K K Saikin Kagaku Kenkyujo, Sendaishi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHN | Withdrawal |